(VIANEWS) - Tattooed Chef (TTCF), China Petroleum & Chemical (SNP), Arcelor Mittal (MT) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Tattooed Chef (TTCF)
81.2% sales growth and 56.23% return on equity
Tattooed Chef's sales growth this year is anticipated to be 61.2% and 34.9% for next year.
Year-on-year quarterly revenue growth grew by 47.7%, now sitting on 148.49M for the twelve trailing months.
Volume
Today's last reported volume for Tattooed Chef is 155828 which is 91.32% below its average volume of 1796510.
Tattooed Chef's sales growth is a negative 0% for the current quarter and 81.2% for the next. The company's growth estimates for the current quarter and the next is a negative 0% and negative -200%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 56.23%.
Volatility
Tattooed Chef's last day, last week, and last month's current volatility was 3.24%, 6.48%, and 2.79%, respectively.
Tattooed Chef's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 4.20% (day), 6.70% (last week), and 4.37% (last month), respectively.
Tattooed Chef's Stock Yearly Top and Bottom Value
Tattooed Chef's stock is valued at $19.38 at 11:22 EST, way below its 52-week high of $28.64 and way above its 52-week low of $14.09.
Tattooed Chef's Moving Average
Tattooed Chef's worth is above its 50-day moving average of $19.36 and below its 200-day moving average of $19.95.2. China Petroleum & Chemical (SNP)
64.5% sales growth and 12.96% return on equity
China Petroleum & Chemical Corporation, an energy and chemical company, engages in oil and gas, and chemical operations in the People's Republic of China.
China Petroleum & Chemical's sales growth this year is expected to be 39.6% and 7% for next year.
Year-on-year quarterly revenue growth grew by 43.1%, now sitting on 2.33T for the twelve trailing months.
Volume
Today's last reported volume for China Petroleum & Chemical is 29176 which is 82.52% below its average volume of 166957.
China Petroleum & Chemical's sales growth for the next quarter is 64.5%. The company's growth estimates for the current quarter and the next is 60.6% and 158%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 12.96%.
Volatility
China Petroleum & Chemical's last day, last week, and last month's current volatility was 2.28%, 1.92%, and 1.53%, respectively.
China Petroleum & Chemical's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 1.15% (day), 1.13% (last week), and 1.27% (last month), respectively.
China Petroleum & Chemical's Stock Yearly Top and Bottom Value
China Petroleum & Chemical's stock is valued at $49.68 at 11:22 EST, way under its 52-week high of $58.40 and way above its 52-week low of $38.18.
China Petroleum & Chemical's Moving Average
China Petroleum & Chemical's value is above its 50-day moving average of $46.94 and below its 200-day moving average of $51.09.3. Arcelor Mittal (MT)
47.1% sales growth and 18.21% return on equity
ArcelorMittal, together with its subsidiaries, owns and operates steel manufacturing and mining facilities in Europe, North and South America, Asia, and Africa.
Arcelor Mittal's sales growth this year is anticipated to be 46.1% and a negative 11.5% for next year.
Year-on-year quarterly revenue growth grew by 76.2%, now sitting on 62.99B for the twelve trailing months.
Volume
Today's last reported volume for Arcelor Mittal is 1141160 which is 69.15% below its average volume of 3699430.
Arcelor Mittal's sales growth for the next quarter is 47.1%. The company's growth estimates for the present quarter and the next is 2536.8% and 1826.3%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 18.21%.
Volatility
Arcelor Mittal's last day, last week, and last month's current volatility was 0.51%, 1.28%, and 1.63%, respectively.
Arcelor Mittal's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 2.24% (day), 2.32% (last week), and 2.19% (last month), respectively.
Arcelor Mittal's Stock Yearly Top and Bottom Value
Arcelor Mittal's stock is valued at $33.49 at 11:22 EST, under its 52-week high of $36.58 and way above its 52-week low of $11.84.
Arcelor Mittal's Moving Average
Arcelor Mittal's value is below its 50-day moving average of $34.22 and higher than its 200-day moving average of $31.01.4. Neurocrine Biosciences (NBIX)
30.2% sales growth and 34.56% return on equity
Neurocrine Biosciences, Inc., a neuroscience-focused biopharmaceutical company, discovers, develops, and delivers various treatments for people with neurological, endocrine, and psychiatric disorders.
Neurocrine Biosciences's sales growth this year is expected to be 9% and 23.4% for next year.
Year-on-year quarterly revenue growth declined by 4.5%, now sitting on 1.03B for the twelve trailing months.
Volume
Today's last reported volume for Neurocrine Biosciences is 451549 which is 33.59% below its average volume of 679980.
Neurocrine Biosciences's sales growth for the next quarter is 30.2%. The company's growth estimates for the ongoing quarter and the next is 193.5% and negative -80.2%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 34.56%.
Volatility
Neurocrine Biosciences's last day, last week, and last month's current volatility was 2.20%, 1.21%, and 1.30%, respectively.
Neurocrine Biosciences's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 3.42% (day), 2.78% (last week), and 2.67% (last month), respectively.
Neurocrine Biosciences's Stock Yearly Top and Bottom Value
Neurocrine Biosciences's stock is valued at $94.62 at 11:22 EST, way under its 52-week high of $120.27 and way above its 52-week low of $84.77.
Neurocrine Biosciences's Moving Average
Neurocrine Biosciences's value is higher than its 50-day moving average of $92.96 and below its 200-day moving average of $95.06.5. Extra Space Storage (EXR)
10.2% sales growth and 20.26% return on equity
Extra Space Storage Inc., headquartered in Salt Lake City, Utah, is a self-administered and self-managed REIT and a member of the S&P 500.
Extra Space Storage's sales growth this year is expected to be 11.7% and 6.1% for next year.
Year-on-year quarterly revenue growth grew by 8.4%, now sitting on 1.41B for the twelve trailing months.
Volume
Today's last reported volume for Extra Space Storage is 50623 which is 93.67% below its average volume of 800228.
Extra Space Storage's sales growth is a negative 0% for the ongoing quarter and 10.2% for the next. The company's growth estimates for the present quarter and the next is 37.5% and 1.7%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 20.26%.
Volatility
Extra Space Storage's last day, last week, and last month's current volatility was 1.10%, 1.10%, and 0.77%, respectively.
Extra Space Storage's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 1.91% (day), 1.68% (last week), and 1.45% (last month), respectively.
Extra Space Storage's Stock Yearly Top and Bottom Value
Extra Space Storage's stock is valued at $183.33 at 11:22 EST, under its 52-week high of $194.67 and way higher than its 52-week low of $102.74.
Extra Space Storage's Moving Average
Extra Space Storage's value is higher than its 50-day moving average of $179.99 and way above its 200-day moving average of $156.57.6. Acadia Healthcare Company (ACHC)
7.9% sales growth and 6.68% return on equity
Acadia Healthcare Company, Inc. develops and operates inpatient psychiatric facilities, residential treatment centers, group homes, substance abuse facilities, and outpatient behavioral healthcare facilities to serve the behavioral health and recovery needs of communities in the United States, the United Kingdom, and Puerto Rico.
Acadia Healthcare Company's sales growth this year is anticipated to be 10.4% and 7% for next year.
Year-on-year quarterly revenue growth grew by 18.5%, now sitting on 2.22B for the twelve trailing months.
Volume
Today's last reported volume for Acadia Healthcare Company is 189585 which is 49.16% below its average volume of 372915.
Acadia Healthcare Company's sales growth is a negative 0% for the current quarter and 7.9% for the next. The company's growth estimates for the current quarter and the next is 5.9% and negative -38.1%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 6.68%.
Volatility
Acadia Healthcare Company's last day, last week, and last month's current volatility was 0.56%, 1.18%, and 1.46%, respectively.
Acadia Healthcare Company's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 2.08% (day), 2.67% (last week), and 2.76% (last month), respectively.
Acadia Healthcare Company's Stock Yearly Top and Bottom Value
Acadia Healthcare Company's stock is valued at $65.02 at 11:22 EST, below its 52-week high of $68.65 and way above its 52-week low of $27.07.